{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:13:26Z","timestamp":1784560406720,"version":"3.55.0"},"reference-count":79,"publisher":"Japanese Society of Toxicology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2131\/jts.51.379","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:19:13Z","timestamp":1782857953000},"page":"379-391","source":"Crossref","is-referenced-by-count":1,"title":["Protein homeostasis disruption in cisplatin-induced skeletal muscle atrophy: toxicological insights from experimental studies"],"prefix":"10.2131","volume":"51","author":[{"given":"Hiroyasu","family":"Sakai","sequence":"first","affiliation":[{"name":"Department of Toxicology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risako","family":"Kon","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutomo","family":"Ikarashi","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Toxicology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Alberts, D.S. and Noel, J.K. (1995): Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs, <b>6<\/b>, 369-383.","DOI":"10.1097\/00001813-199506000-00003"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Au, P.C., Li, H.L., Lee, G.K., Li, G.H., Chan, M., Cheung, B.M., Wong, I.C., Lee, V.H., Mok, J., Yip, B.H., Cheng, K.K., Wu, C.H. and Cheung, C.L. (2021): Sarcopenia and mortality in cancer: A meta-analysis. Osteoporos. Sarcopenia, <b>7<\/b> (Suppl 1), S28-S33.","DOI":"10.1016\/j.afos.2021.03.002"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Aversa, Z., Costelli, P. and Muscaritoli, M. (2017): Cancer-induced muscle wasting: latest findings in prevention and treatment. Ther. Adv. Med. Oncol., <b>9<\/b>, 369-382.","DOI":"10.1177\/1758834017698643"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bae, J.H., Seo, D.Y., Lee, S.H., Shin, C., Jamrasi, P., Han, J. and Song, W. (2021): Effects of exercise on AKT\/PGC1-\u03b1\/FOXO3a pathway and muscle atrophy in cisplatin-administered rat skeletal muscle. Korean J. Physiol. Pharmacol., <b>25<\/b>, 585-592.","DOI":"10.4196\/kjpp.2021.25.6.585"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Barabas, K., Milner, R., Lurie, D. and Adin, C. (2008): Cisplatin: a review of toxicities and therapeutic applications. Vet. Comp. Oncol., <b>6<\/b>, 1-18.","DOI":"10.1111\/j.1476-5829.2007.00142.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C. and Fearon, K.C. (2018): Cancer-associated cachexia. Nat. Rev. Dis. Primers, <b>4<\/b>, 17105.","DOI":"10.1038\/nrdp.2017.105"},{"key":"7","doi-asserted-by":"publisher","unstructured":"Bostr\u00f6m, P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., Rasbach, K.A., Bostr\u00f6m, E.A., Choi, J.H., Long, J.Z., Kajimura, S., Zingaretti, M.C., Vind, B.F., Tu, H., Cinti, S., H\u00f8jlund, K., Gygi, S.P. and Spiegelman, B.M. (2012): A PGC1-\u03b1-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, <b>481<\/b>, 463-468.","DOI":"10.1038\/nature10777"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Campelj, D.G., Goodman, C.A. and Rybalka, E. (2021): Chemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere. Cancers (Basel), <b>13<\/b>, 3615.","DOI":"10.3390\/cancers13143615"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Chen, K., Wang, K. and Wang, T. (2022): Protective effect of irisin against Alzheimer\u2019s disease. Front. Psychiatry, <b>13<\/b>, 967683.","DOI":"10.3389\/fpsyt.2022.967683"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Chi, M.Y., Zhang, H., Wang, Y.X., Sun, X.P., Yang, Q.J. and Guo, C. (2022): Silibinin Alleviates Muscle Atrophy Caused by Oxidative Stress Induced by Cisplatin through ERK\/FoxO and JNK\/FoxO Pathways. Oxid. Med. Cell. Longev., <b>2022<\/b>, 5694223.","DOI":"10.1155\/2022\/5694223"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Conte, E., Bresciani, E., Rizzi, L., Cappellari, O., De Luca, A., Torsello, A. and Liantonio, A. (2020): Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies. Int. J. Mol. Sci., <b>21<\/b>, 1242.","DOI":"10.3390\/ijms21041242"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Crona, D.J., Faso, A., Nishijima, T.F., McGraw, K.A., Galsky, M.D. and Milowsky, M.I. (2017): A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist, <b>22<\/b>, 609-619.","DOI":"10.1634\/theoncologist.2016-0319"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Dasari, S. and Tchounwou, P.B. (2014): Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol., <b>740<\/b>, 364-378.","DOI":"10.1016\/j.ejphar.2014.07.025"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Deutz, N.E., Bauer, J.M., Barazzoni, R., Biolo, G., Boirie, Y., Bosy-Westphal, A., Cederholm, T., Cruz-Jentoft, A., Krznari\u00e7, Z., Nair, K.S., Singer, P., Teta, D., Tipton, K. and Calder, P.C. (2014): Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin. Nutr., <b>33<\/b>, 929-936.","DOI":"10.1016\/j.clnu.2014.04.007"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Donohoe, C.L., Ryan, A.M. and Reynolds, J.V. (2011): Cancer cachexia: mechanisms and clinical implications. Gastroenterol. Res. Pract., <b>2011<\/b>, 601434.","DOI":"10.1155\/2011\/601434"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Ebert, S.M., Bullard, S.A., Basisty, N., Marcotte, G.R., Skopec, Z.P., Dierdorff, J.M., Al-Zougbi, A., Tomcheck, K.C., DeLau, A.D., Rathmacher, J.A., Bodine, S.C., Schilling, B. and Adams, C.M. (2020): Activating transcription factor 4 (ATF4) promotes skeletal muscle atrophy by forming a heterodimer with the transcriptional regulator C\/EBP\u03b2. J. Biol. Chem., <b>295<\/b>, 2787-2803.","DOI":"10.1074\/jbc.RA119.012095"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Elmorsy, E.A., Saber, S., Hamad, R.S., Abdel-Reheim, M.A., El-Kott, A.F., AlShehri, M.A., Morsy, K., Salama, S.A. and Youssef, M.E. (2024): Advances in understanding cisplatin-induced toxicity: molecular mechanisms and protective strategies. Eur. J. Pharm. Sci., <b>203<\/b>, 106939.","DOI":"10.1016\/j.ejps.2024.106939"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Fanzani, A., Zanola, A., Rovetta, F., Rossi, S. and Aleo, M.F. (2011): Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems. Toxicol. Appl. Pharmacol., <b>250<\/b>, 312-321.","DOI":"10.1016\/j.taap.2010.11.003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., Davis, M., Muscaritoli, M., Ottery, F., Radbruch, L., Ravasco, P., Walsh, D., Wilcock, A., Kaasa, S. and Baracos, V.E. (2011): Definition and classification of cancer cachexia: an international consensus. Lancet Oncol., <b>12<\/b>, 489-495.","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D. and Dou, Q.P. (2010): Novel metals and metal complexes as platforms for cancer therapy. Curr. Pharm. Des., <b>16<\/b>, 1813-1825.","DOI":"10.2174\/138161210791209009"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M. and Kroemer, G. (2014): Systems biology of cisplatin resistance: past, present and future. Cell Death Dis., <b>5<\/b>, e1257.","DOI":"10.1038\/cddis.2013.428"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Glass, D.J. (2003): Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat. Cell Biol., <b>5<\/b>, 87-90.","DOI":"10.1038\/ncb0203-87"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Goedendorp, M.M., Andrykowski, M.A., Donovan, K.A., Jim, H.S., Phillips, K.M., Small, B.J., Laronga, C. and Jacobsen, P.B. (2012): Prolonged impact of chemotherapy on fatigue in breast cancer survivors: a longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls. Cancer, <b>118<\/b>, 3833-3841.","DOI":"10.1002\/cncr.26226"},{"key":"24","doi-asserted-by":"publisher","unstructured":"Haberecht-M\u00fcller, S., Kr\u00fcger, E. and Fielitz, J. (2021): Out of Control: The Role of the Ubiquitin Proteasome System in Skeletal Muscle during Inflammation. Biomolecules, <b>11<\/b>, 1327.","DOI":"10.3390\/biom11091327"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Hellmann, M.D., Li, B.T., Chaft, J.E. and Kris, M.G. (2016): Chemotherapy remains an essential element of personalized care for persons with lung cancers. Ann. Oncol., <b>27<\/b>, 1829-1835.","DOI":"10.1093\/annonc\/mdw271"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Hojman, P., Fjelbye, J., Zerahn, B., Christensen, J.F., Dethlefsen, C., Lonkvist, C.K., Brandt, C., Gissel, H., Pedersen, B.K. and Gehl, J. (2014): Voluntary exercise prevents cisplatin-induced muscle wasting during chemotherapy in mice. PLoS One, <b>9<\/b>, e109030.","DOI":"10.1371\/journal.pone.0109030"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Hong, M., Han, I.H., Choi, I., Cha, N., Kim, W., Kim, S.K. and Bae, H. (2021): Magnoliae Cortex Alleviates Muscle Wasting by Modulating M2 Macrophages in a Cisplatin-Induced Sarcopenia Mouse Model. Int. J. Mol. Sci., <b>22<\/b>, 3188.","DOI":"10.3390\/ijms22063188"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Huang, K.C., Chiang, Y.F., Ali, M. and Hsia, S.M. (2025): Cisplatin-Induced Muscle Wasting and Atrophy: Molecular Mechanism and Potential Therapeutic Interventions. J. Cachexia Sarcopenia Muscle, <b>16<\/b>, e13817.","DOI":"10.1002\/jcsm.13817"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Huang, K.C., Chiang, Y.F., Huang, T.C., Chen, H.Y., Lin, P.H., Ali, M. and Hsia, S.M. (2023): Capsaicin alleviates cisplatin-induced muscle loss and atrophy <i>in vitro<\/i> and <i>in vivo.<\/i> J. Cachexia Sarcopenia Muscle, <b>14<\/b>, 182-197.","DOI":"10.1002\/jcsm.13120"},{"key":"30","unstructured":"Huot, J.R., Pin, F. and Bonetto, A. (2021): Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity. Am. J. Cancer Res., <b>11<\/b>, 2990-3001."},{"key":"31","doi-asserted-by":"crossref","unstructured":"Ikeno, Y., Inomata, M., Tsukimura, Y., Suzuki, Y., Takeuchi, H., Harada, Y., Kon, R., Ikarashi, N., Chiba, Y., Yamada, T., Kamei, J. and Sakai, H. (2022): Eicosapentaenoic acid suppresses cisplatin-induced muscle atrophy by attenuating the up-regulated gene expression of ubiquitin. J. Nutr. Biochem., <b>103<\/b>, 108953.","DOI":"10.1016\/j.jnutbio.2022.108953"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Jordan, P. and Carmo-Fonseca, M. (2000): Molecular mechanisms involved in cisplatin cytotoxicity. Cell. Mol. Life Sci., <b>57<\/b>, 1229-1235.","DOI":"10.1007\/PL00000762"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Kelland, L. (2007): The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, <b>7<\/b>, 573-584.","DOI":"10.1038\/nrc2167"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Le Bacquer, O., Sanchez, P., Patrac, V., Rivoirard, C., Saroul, N., Giraudet, C., Kocer, A. and Walrand, S. (2024): Cannabidiol protects C2C12 myotubes against cisplatin-induced atrophy by regulating oxidative stress. Am. J. Physiol. Cell Physiol., <b>326<\/b>, C1226-C1236.","DOI":"10.1152\/ajpcell.00622.2023"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Lecker, S.H., Jagoe, R.T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S.R., Mitch, W.E. and Goldberg, A.L. (2004): Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J., <b>18<\/b>, 39-51.","DOI":"10.1096\/fj.03-0610com"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Li, Y.P. and Reid, M.B. (2000): NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am. J. Physiol. Regul. Integr. Comp. Physiol., <b>279<\/b>, R1165-R1170.","DOI":"10.1152\/ajpregu.2000.279.4.R1165"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Li, Y.P., Schwartz, R.J., Waddell, I.D., Holloway, B.R. and Reid, M.B. (1998): Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J., <b>12<\/b>, 871-880.","DOI":"10.1096\/fasebj.12.10.871"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Matsumoto, C., Sekine, H., Nahata, M., Mogami, S., Ohbuchi, K., Fujitsuka, N. and Takeda, H. (2022): Role of Mitochondrial Dysfunction in the Pathogenesis of Cisplatin-Induced Myotube Atrophy. Biol. Pharm. Bull., <b>45<\/b>, 780-792.","DOI":"10.1248\/bpb.b22-00171"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Miyauchi, Y., Soga, S., Nanri, H., Yonamine, S., Ogiwara, T., Kiyama, M., Kon, R., Ikarashi, N., Chiba, Y., Hosoe, T. and Sakai, H. (2025): Decreased Expression and Secretion of the Myokine Fndc5\/Irisin by Cisplatin Treatment in Mouse Skeletal Muscle. Calcif. Tissue Int., <b>116<\/b>, 96.","DOI":"10.1007\/s00223-025-01406-5"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Nanri, H., Sakai, H., Soga, S., Chigusa, Y., Ichikawa, R., Kon, R., Ikarashi, N., Chiba, Y. and Ogawa, K. (2026): Cisplatin-associated transcriptional changes in ER stress-related genes in skeletal muscle and C2C12 myotubes. Toxicol. Mech. Methods, <b>36<\/b>, 698-706.","DOI":"10.1080\/15376516.2026.2639053"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Novinger, L.J., Weinzierl, N.M. and Bonetto, A. (2025): Diversity in chemotherapy-induced cachexia. Am. J. Physiol. Cell Physiol., <b>328<\/b>, C139-C147.","DOI":"10.1152\/ajpcell.00773.2024"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Ogata, M., Hino, S., Saito, A., Morikawa, K., Kondo, S., Kanemoto, S., Murakami, T., Taniguchi, M., Tanii, I., Yoshinaga, K., Shiosaka, S., Hammarback, J.A., Urano, F. and Imaizumi, K. (2006): Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol. Cell. Biol., <b>26<\/b>, 9220-9231.","DOI":"10.1128\/MCB.01453-06"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Oh, J.J. and Hong, S.K. (2025): Contemporary management of metastatic urothelial carcinoma. Investig. Clin. Urol., <b>66<\/b>, 375-382.","DOI":"10.4111\/icu.20250008"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Osaki, K., Fukushima, T., Suzuki, K., Kamimura, A., Yanai, S. and Morishita, S. (2024): Current status of research on sarcopenia in post-treatment cancer survivors in Japan:A narrative review. Fukushima J. Med. Sci., <b>70<\/b>, 119-131.","DOI":"10.5387\/fms.23-00019"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Paddon-Jones, D., Short, K.R., Campbell, W.W., Volpi, E. and Wolfe, R.R. (2008): Role of dietary protein in the sarcopenia of aging. Am. J. Clin. Nutr., <b>87<\/b>, 1562S-1566S.","DOI":"10.1093\/ajcn\/87.5.1562S"},{"key":"46","unstructured":"Pirker, R. (2014): Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. Transl. Lung Cancer Res., <b>3<\/b>, 305-310."},{"key":"47","doi-asserted-by":"crossref","unstructured":"Prado, C.M., Lieffers, J.R., McCargar, L.J., Reiman, T., Sawyer, M.B., Martin, L. and Baracos, V.E. (2008): Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol., <b>9<\/b>, 629-635.","DOI":"10.1016\/S1470-2045(08)70153-0"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Rom, O. and Reznick, A.Z. (2016): The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass. Free Radic. Biol. Med., <b>98<\/b>, 218-230.","DOI":"10.1016\/j.freeradbiomed.2015.12.031"},{"key":"49","doi-asserted-by":"publisher","unstructured":"Rosenberg, B., Vancamp, L. and Krigas, T. (1965): Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode. Nature, <b>205<\/b>, 698-699.","DOI":"10.1038\/205698a0"},{"key":"50","doi-asserted-by":"publisher","unstructured":"Rosenberg, B., VanCamp, L., Trosko, J.E. and Mansour, V.H. (1969): Platinum compounds: a new class of potent antitumour agents. Nature, <b>222<\/b>, 385-386.","DOI":"10.1038\/222385a0"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Sakai, H., Asami, M., Naito, H., Kitora, S., Suzuki, Y., Miyauchi, Y., Tachinooka, R., Yoshida, S., Kon, R., Ikarashi, N., Chiba, Y. and Kamei, J. (2021): Exogenous insulin-like growth factor 1 attenuates cisplatin-induced muscle atrophy in mice. J. Cachexia Sarcopenia Muscle, <b>12<\/b>, 1570-1581.","DOI":"10.1002\/jcsm.12760"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Sakai, H., Ikeno, Y., Tsukimura, Y., Inomata, M., Suzuki, Y., Kon, R., Ikarashi, N., Chiba, Y., Yamada, T. and Kamei, J. (2020): Upregulation of ubiquitinated proteins and their degradation pathway in muscle atrophy induced by cisplatin in mice. Toxicol. Appl. Pharmacol., <b>403<\/b>, 115165.","DOI":"10.1016\/j.taap.2020.115165"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Sakai, H., Kimura, M., Isa, Y., Yabe, S., Maruyama, A., Tsuruno, Y., Kai, Y., Sato, F., Yumoto, T., Chiba, Y. and Narita, M. (2017): Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse. Pflugers Arch., <b>469<\/b>, 1495-1505.","DOI":"10.1007\/s00424-017-2045-4"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Sakai, H., Kimura, M., Tsukimura, Y., Yabe, S., Isa, Y., Kai, Y., Sato, F., Kon, R., Ikarashi, N., Narita, M., Chiba, Y. and Kamei, J. (2019): Dexamethasone exacerbates cisplatin-induced muscle atrophy. Clin. Exp. Pharmacol. Physiol., <b>46<\/b>, 19-28.","DOI":"10.1111\/1440-1681.13024"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Sakai, H., Sagara, A., Arakawa, K., Sugiyama, R., Hirosaki, A., Takase, K., Jo, A., Sato, K., Chiba, Y., Yamazaki, M., Matoba, M. and Narita, M. (2014): Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol., <b>278<\/b>, 190-199.","DOI":"10.1016\/j.taap.2014.05.001"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Sakai, H., Suzuki, Y., Miyauchi, Y., Sato, F., Ando, Y., Kon, R., Ikarashi, N., Chiba, Y., Kamei, J. and Hosoe, T. (2022a): Downregulation of Sparc-like protein 1 during cisplatin-induced inhibition of myogenic differentiation of C2C12 myoblasts. Biochem. Pharmacol., <b>204<\/b>, 115234.","DOI":"10.1016\/j.bcp.2022.115234"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Sakai, H., Zhou, Y., Miyauchi, Y., Suzuki, Y., Ikeno, Y., Kon, R., Ikarashi, N., Chiba, Y., Hosoe, T. and Kamei, J. (2022b): Increased 20S Proteasome Expression and the Effect of Bortezomib during Cisplatin-Induced Muscle Atrophy. Biol. Pharm. Bull., <b>45<\/b>, 910-918.","DOI":"10.1248\/bpb.b22-00177"},{"key":"58","doi-asserted-by":"publisher","unstructured":"Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S.H. and Goldberg, A.L. (2004): Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell, <b>117<\/b>, 399-412.","DOI":"10.1016\/S0092-8674(04)00400-3"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Sato, K., Miyauchi, Y., Xu, X., Kon, R., Ikarashi, N., Chiba, Y., Hosoe, T. and Sakai, H. (2023): Platinum-based anticancer drugs-induced downregulation of myosin heavy chain isoforms in skeletal muscle of mouse. J. Pharmacol. Sci., <b>152<\/b>, 167-177.","DOI":"10.1016\/j.jphs.2023.04.009"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Sato, K., Satoshi, Y., Miyauchi, Y., Sato, F., Kon, R., Ikarashi, N., Chiba, Y., Hosoe, T. and Sakai, H. (2024): Downregulation of PGC-1\u03b1 during cisplatin-induced muscle atrophy in murine skeletal muscle. Biochim. Biophys. Acta Mol. Basis Dis., <b>1870<\/b>, 166877.","DOI":"10.1016\/j.bbadis.2023.166877"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Sekine, H., Matsumoto, C., Fujitsuka, N., Mogami, S., Ohnishi, S. and Takeda, H. (2025): Hochuekkito accelerates recovery from cisplatin induced-muscle atrophy accompanied by slow-twitch fiber-specific microRNA upregulation in mice. Front. Pharmacol., <b>16<\/b>, 1502563.","DOI":"10.3389\/fphar.2025.1502563"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Seo, D.Y., Bae, J.H., Zhang, D., Song, W., Kwak, H.B., Heo, J.W., Jung, S.J., Yun, H.R., Kim, T.N., Lee, S.H., Kim, A.H., Jeong, D.H., Kim, H.K. and Han, J. (2021): Effects of cisplatin on mitochondrial function and autophagy-related proteins in skeletal muscle of rats. BMB Rep., <b>54<\/b>, 575-580.","DOI":"10.5483\/BMBRep.2021.54.11.132"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Shachar, S.S., Williams, G.R., Muss, H.B. and Nishijima, T.F. (2016): Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur. J. Cancer, <b>57<\/b>, 58-67.","DOI":"10.1016\/j.ejca.2015.12.030"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Sikking, C., Niggebrugge-Mentink, K.L., van der Sman, A.S., Smit, R.H., Bouman-Wammes, E.W., Beex-Oosterhuis, M.M. and van Kesteren, C. (2024): Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review. Oncologist, <b>29<\/b>, e173-e186.","DOI":"10.1093\/oncolo\/oyad297"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Soga, S., Nanri, H., Sakai, H., Ichikawa, R., Chigusa, Y., Urase, Y., Yonamine, S., Ogiwara, T., Kon, R., Ikarashi, N., Chiba, Y., Hosoe, T. and Ogawa, K. (2026): Potential involvement of the endoplasmic reticulum stress response in the development of cisplatin-induced muscle atrophy. J. Toxicol. Sci., <b>51<\/b>, 123-130.","DOI":"10.2131\/jts.51.123"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Stacchiotti, A., Rovetta, F., Ferroni, M., Corsetti, G., Lavazza, A., Sberveglieri, G. and Aleo, M.F. (2014): Taurine rescues cisplatin-induced muscle atrophy <i>in vitro<\/i>: a morphological study. Oxid. Med. Cell. Longev., <b>2014<\/b>, 840951.","DOI":"10.1155\/2014\/840951"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Sturgeon, K.M., Mathis, K.M., Rogers, C.J., Schmitz, K.H. and Waning, D.L. (2019): Cancer- and Chemotherapy-Induced Musculoskeletal Degradation. JBMR Plus, <b>3<\/b>, e10187.","DOI":"10.1002\/jbm4.10187"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Taillandier, D., Combaret, L., Pouch, M.N., Samuels, S.E., B\u00e9chet, D. and Attaix, D. (2004): The role of ubiquitin-proteasome-dependent proteolysis in the remodelling of skeletal muscle. Proc. Nutr. Soc., <b>63<\/b>, 357-361.","DOI":"10.1079\/PAR2004358"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Wu, C.T., Liao, J.M., Ko, J.L., Lee, Y.L., Chang, H.Y., Wu, C.H. and Ou, C.C. (2019): D-Methionine Ameliorates Cisplatin-Induced Muscle Atrophy via Inhibition of Muscle Degradation Pathway. Integr. Cancer Ther., <b>18<\/b>, 1534735419828832.","DOI":"10.1177\/1534735419828832"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Wu, Y., Pi, D., Zhou, S., Wang, W., Ye, H., Yi, Z., Chen, Y. and Ouyang, M. (2023): Yiqi Chutan Formula Reverses Cisplatin-Induced Apoptosis and Ferroptosis of Skeletal Muscle by Alleviating Oxidative Stress. Integr. Cancer Ther., <b>22<\/b>, 15347354231172117.","DOI":"10.1177\/15347354231172117"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Xia, Q., Huang, X., Huang, J., Zheng, Y., March, M.E., Li, J. and Wei, Y. (2021): The Role of Autophagy in Skeletal Muscle Diseases. Front. Physiol., <b>12<\/b>, 638983.","DOI":"10.3389\/fphys.2021.638983"},{"key":"72","doi-asserted-by":"publisher","unstructured":"Xu, M. and Liu, X. (2025): Cisplatin-Induced Skeletal Muscle Atrophy: Biomolecular Mechanisms and the Protective Role of Exercise-Induced Myokines. Biomolecules, <b>15<\/b>, 1495.","DOI":"10.3390\/biom15111495"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Yang, Y., Liu, H., Liu, F. and Dong, Z. (2014): Mitochondrial dysregulation and protection in cisplatin nephrotoxicity. Arch. Toxicol., <b>88<\/b>, 1249-1256.","DOI":"10.1007\/s00204-014-1239-1"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Yeh, S.L., Chen, P.Y., Liao, J.W., Huang, R.L., Yu, S.H., Chen, L.N., Lee, M.H., Chen, L.W., Chen, H.W., Yang, Y.C., Wu, Y.L. and Liu, K.L. (2025): The Protective Effects of Perch Essence Against Muscle Atrophy in Cancer Cachexia and Cisplatin Treatment. Curr. Issues Mol. Biol., <b>47<\/b>, 152.","DOI":"10.3390\/cimb47030152"},{"key":"75","doi-asserted-by":"crossref","unstructured":"You, L. (2024): Dihydromyricetin Inhibits Ferroptosis to Attenuate Cisplatin-Induced Muscle Atrophy. Physiol. Res., <b>73<\/b>, 405-413.","DOI":"10.33549\/physiolres.935317"},{"key":"76","doi-asserted-by":"crossref","unstructured":"Zhang, H., Chi, M., Chen, L., Sun, X., Wan, L., Yang, Q. and Guo, C. (2020): Linalool Prevents Cisplatin Induced Muscle Atrophy by Regulating IGF-1\/Akt\/FoxO Pathway. Front. Pharmacol., <b>11<\/b>, 598166.","DOI":"10.3389\/fphar.2020.598166"},{"key":"77","doi-asserted-by":"crossref","unstructured":"Zhang, H., Chi, M., Chen, L., Sun, X., Wan, L., Yang, Q. and Guo, C. (2021): Daidzein alleviates cisplatin-induced muscle atrophy by regulating Glut4\/AMPK\/FoxO pathway. Phytother. Res., <b>35<\/b>, 4363-4376.","DOI":"10.1002\/ptr.7132"},{"key":"78","doi-asserted-by":"crossref","unstructured":"Zhang, H., Wu, X., Liang, J., Kirberger, M. and Chen, N. (2022): Irisin, an exercise-induced bioactive peptide beneficial for health promotion during aging process. Ageing Res. Rev., <b>80<\/b>, 101680.","DOI":"10.1016\/j.arr.2022.101680"},{"key":"79","doi-asserted-by":"crossref","unstructured":"Zhong, R., Yang, W., Li, G., Xie, S., Guo, X., Zhou, J., Ren, B. and Zhu, Y. (2022): Nomegestrol acetate ameliorated adipose atrophy in a rat model of cisplatin-induced cachexia. Exp. Ther. Med., <b>25<\/b>, 24.","DOI":"10.3892\/etm.2022.11723"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/51\/7\/51_379\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:28:21Z","timestamp":1783139301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/51\/7\/51_379\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.51.379","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}